<code id='8FF4363F65'></code><style id='8FF4363F65'></style>
    • <acronym id='8FF4363F65'></acronym>
      <center id='8FF4363F65'><center id='8FF4363F65'><tfoot id='8FF4363F65'></tfoot></center><abbr id='8FF4363F65'><dir id='8FF4363F65'><tfoot id='8FF4363F65'></tfoot><noframes id='8FF4363F65'>

    • <optgroup id='8FF4363F65'><strike id='8FF4363F65'><sup id='8FF4363F65'></sup></strike><code id='8FF4363F65'></code></optgroup>
        1. <b id='8FF4363F65'><label id='8FF4363F65'><select id='8FF4363F65'><dt id='8FF4363F65'><span id='8FF4363F65'></span></dt></select></label></b><u id='8FF4363F65'></u>
          <i id='8FF4363F65'><strike id='8FF4363F65'><tt id='8FF4363F65'><pre id='8FF4363F65'></pre></tt></strike></i>

          Home / entertainment / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:2648

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In